JUBILANT-PHARMOVA-LTD

About Jubilant Pharmova Ltd

Jubilant Pharmova Ltd. is a global pharmaceutical company focused on specialty pharmaceuticals including radiopharmaceuticals, allergy therapy products, and contract manufacturing and development services (CDMO). Operating primarily through Jubilant Pharma and Jubilant Biosys, it serves healthcare needs worldwide with a strong presence in North America, leveraging integrated capabilities in drug discovery and manufacturing.

Key Financial Ratios of Jubilant Pharmova Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Jubilant Pharmova Ltd's P/E ratio (TTM) is N/A, compared to the industry median of 35.80 and large cap median of 35.80.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Jubilant Pharmova Ltd's P/B ratio is N/A, compared to the industry median of 5.91 and large cap median of N/A.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Jubilant Pharmova Ltd's P/S ratio is 0.72, compared to the industry median of 3.50 and large cap median of N/A.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Jubilant Pharmova Ltd's PEG ratio is N/A.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Jubilant Pharmova Ltd's EV/EBITDA ratio is 4.82.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Jubilant Pharmova Ltd's ROE is N/A.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Jubilant Pharmova Ltd's ROA is N/A.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Jubilant Pharmova Ltd's ROCE is N/A.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Jubilant Pharmova Ltd's operating margin is N/A.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Jubilant Pharmova Ltd's net margin is N/A.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Jubilant Pharmova Ltd's current ratio is N/A.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Jubilant Pharmova Ltd's debt-to-equity ratio is N/A.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Jubilant Pharmova Ltd's interest coverage ratio is N/A.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Jubilant Pharmova Ltd's DPS is ₹5.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Jubilant Pharmova Ltd's EPS is N/A.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1978 (as Vam Organic Chemicals Ltd)

• Headquarters: Noida, Uttar Pradesh

• Core Offerings: Radiopharmaceuticals, Allergy Therapy Products, Contract Manufacturing & Development Services (CDMO), Generics, Drug Discovery Services

• Stock Listing: NSE (JUBLPHARMA), BSE (530019)

• Promoter: Jubilant Bhartia Group

History of Jubilant Pharmova Ltd

Jubilant Pharmova was incorporated in 1978 as Vam Organic Chemicals Ltd. Over the decades, it diversified and evolved, becoming Jubilant Organosys Ltd in 2001 and then Jubilant Life Sciences Ltd in 2010. In 2020, the pharmaceuticals and contract research & development services businesses were demerged from Jubilant Life Sciences into a separate listed entity, Jubilant Pharmova Ltd, to create focused growth opportunities.

Business Segments and Revenue Mix

• Jubilant Pharma: Encompasses Radiopharmaceuticals, Allergy Therapy Products, Sterile Injectables CDMO, and Generics. This segment holds a significant market presence, particularly in North America.

• Jubilant Biosys: Offers comprehensive contract research and development services (CDMO-DDS) for drug discovery, covering areas like discovery chemistry, biology, and medicinal informatics.

• Jubilant Therapeutics: Focuses on proprietary novel drug discovery, developing first-in-class small molecule therapeutics primarily in oncology and autoimmune diseases.

Key Personnel

Hari S Bhartia: Co-Chairman & Managing Director. A visionary entrepreneur, he co-founded the Jubilant Bhartia Group, building a diversified global enterprise with significant presence in pharmaceuticals and other sectors.

Subsidiaries and Associate Companies

• Jubilant Pharma Limited (Singapore): Holding company for the pharmaceutical business.

• Jubilant HollisterStier LLC (USA): Key for contract manufacturing of sterile injectables.

• Jubilant DraxImage Inc. (Canada): Focused on radiopharmaceuticals.

• Jubilant Biosys Limited (India): Operates the contract research and development services.

Corporate Actions

2020: Major demerger of the pharmaceuticals and contract research businesses from Jubilant Life Sciences Limited to form Jubilant Pharmova Ltd, aimed at unlocking shareholder value and creating distinct business focuses.

References

1. Annual Report FY2024
2. Exchange Filings (NSE/BSE)
3. Financial Results Announcement Q4 FY2024